More

    ELAHERE ® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients



    [
    ELAHERE ® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients
    [og_img]
    https://www.investing.com/news/press-releases/elahere–mirvetuximab-soravtansinegynx-shows-consistent-survival-benefit-in-longterm-analysis-for-certain-ovarian-cancer-patients-93CH-3930732


    Investing.com

    Latest articles

    spot_imgspot_img

    Related articles

    Leave a reply

    Please enter your comment!
    Please enter your name here

    spot_imgspot_img